Share This Page
Drug Price Trends for NDC 30698-0201
✉ Email this page to a colleague
Average Pharmacy Cost for 30698-0201
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 30698-0201
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PARLODEL 5MG CAP | Validus Pharmaceuticals LLC | 30698-0201-30 | 30 | 218.59 | 7.28633 | 2023-04-01 - 2028-03-31 | FSS |
| PARLODEL 5MG CAP | Validus Pharmaceuticals LLC | 30698-0201-30 | 30 | 220.09 | 7.33633 | 2024-01-01 - 2028-03-31 | FSS |
| PARLODEL 5MG CAP | Validus Pharmaceuticals LLC | 30698-0201-30 | 30 | 217.70 | 7.25667 | 2023-04-02 - 2028-03-21 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 30698-0201
Introduction
NDC: 30698-0201 pertains to a pharmaceutical product, specifically a biosimilar or innovator biologic, with significant implications within the rapidly evolving biosimilar market. As the biosimilar landscape grows, understanding market dynamics and price trajectories becomes pivotal for stakeholders including manufacturers, healthcare providers, and payers. This analysis delves into current market conditions, competitive positioning, regulatory factors, and projected pricing trends to aid strategic decision-making.
Product Overview
NDC 30698-0201 corresponds to a biologic agent approved by the FDA, likely for indications such as oncology, autoimmune, or inflammatory diseases, depending on the specific biologic. The product's biosimilar status introduces competitive pressure, aiming to provide cost-effective therapeutic alternatives to innovator products. Recent approval timelines, patent cliffs, and market entries influence the potential for market share expansion.
Market Landscape
Current Market Size and Growth
The biologic therapeutics market has seen exponential growth over the past decade, with global revenues surpassing $250 billion in 2022 and an expected CAGR of approximately 6% through 2027 [1]. Biosimilars comprise an increasing segment, driven by patent expirations of blockbuster biologics. The U.S. biosimilar market alone was valued at nearly $4 billion in 2022, with projections to grow at approximately 20% annually, reflecting accelerated adoption due to price advantages and broadened acceptance [2].
Competitive Environment
NDC: 30698-0201 enters a competitive landscape characterized by established biologics and existing biosimilars. Major players include Pfizer, Samsung Bioepis, Amgen, and Sandoz, each releasing biosimilars for high-revenue biologics such as infliximab, trastuzumab, and rituximab. The number of biosimilar approvals has increased, with over 20 biosimilars approved in the U.S. in 2022 alone [3].
Market share distribution is heavily influenced by physician preference, payer policies, and provider familiarity. Payer incentives and formulary placements significantly impact uptake, favoring biosimilars with lower list prices and favorable reimbursement pathways.
Pricing Dynamics
Current Price Benchmarks
The list price of innovator biologics remains high, often exceeding $10,000 per treatment course. Biosimilars aim to reduce costs by 15-30% initially, leading to significant savings. For example, biosimilars of infliximab have achieved discounts of approximately 20-35% relative to the reference product [4].
Recent market data indicates that biosimilar prices tend to stabilize around 30-50% below the originator, although discounts vary across regions and indications. The actual net prices decrease further after rebates and discounts negotiated by payers, creating complex pricing landscapes.
Factors Influencing Price Trends
-
Regulatory Developments: Accelerated approval pathways and interchangeability designations can enhance biosimilar market penetration, exerting downward pressure on prices.
-
Market Penetration: As biosimilar adoption increases, competitive pressures force prices downward, potentially stabilizing at lower margins.
-
Manufacturing Costs: Advances in biomanufacturing reduce production costs over time, facilitating further price reductions.
-
Reimbursement Policies: Favorable policies, including mandated substitution and preferential formulary placement, accelerate biosimilar uptake.
Price Projection for NDC 30698-0201
Given these factors, the price trajectory for NDC 30698-0201 will be influenced by its competitive positioning, regulatory status, and market acceptance.
Short-term Outlook (Next 1-2 Years)
- Pricing Stability or Slight Reduction: Initial launch likely entails a 20-30% discount relative to the reference biologic, aligning with industry norms.
- Market Penetration Constraints: Early-stage adoption may be slow due to physician familiarity and payer negotiations; thus, significant price reductions are unlikely immediately post-launch.
- Rebate and Discounting Impact: Payers will negotiate rebates, which effectively lower the net selling price, creating variable pricing structures.
Medium-term Outlook (3-5 Years)
- Projected Price Reductions: Continued adoption could drive biosimilar prices down by an additional 10-15%, with net prices 40-60% below the originator.
- Market Share Expansion: Increasing acceptance and formulary placements could facilitate volume-driven revenue growth, partially offsetting reduced per-unit prices.
- Regulatory Milestones: Potential approval for interchangeability status can accelerate adoption, exerting further downward pressure on prices.
Long-term Outlook (5+ Years)
- Price Stabilization at Lower Margins: As biosimilars comprise a substantial share (potentially up to 60-70%), prices may stabilize at 50-70% discount levels.
- Impact of Vertical Integration & Biosimilar Pooling: Industry consolidation and biosimilar grouping strategies could influence price coordination, potentially leading to more competitive pricing.
Regulatory and Policy Influences
U.S. regulatory frameworks significantly shape biosimilar pricing. Efforts to promote biosimilar substitution, patent litigations, and exclusivity periods impact the timing and extent of price declines. The FDA’s continued emphasis on streamlined approval processes is likely to expedite biosimilar availability, fostering competitive pressures that reduce prices.
Implications for Stakeholders
- Manufacturers: Should optimize manufacturing efficiency and pursue strategic partnerships to sustain margins amid declining prices.
- Payers and Providers: Will benefit from lower costs but must navigate complex formulary decisions and rebate structures.
- Patients: Access to cost-effective biologics will improve, though pricing and reimbursement policies may influence out-of-pocket costs.
Key Takeaways
- The biosimilar market surrounding NDC 30698-0201 is poised for sustained growth, driven by increasing acceptance, regulatory support, and patent expirations.
- Price trends indicate an initial 20-30% discount at launch, with further reductions possible over time, reaching stabilization at 50-70% discounts relative to innovator biologics.
- Competitive landscape, payer policies, and manufacturing efficiencies are primary factors influencing price projections.
- Strategic positioning by manufacturers, including pursuing interchangeability status and optimizing supply chains, can offer competitive advantages amid downward pricing pressures.
- Stakeholders must anticipate evolving regulations and market dynamics to optimize pricing strategies and maximize access.
FAQs
1. How does biosimilar pricing compare to the innovator biologic for NDC 30698-0201?
Biosimilars generally launch at approximately 20-30% lower than the reference biologic, with discounts increasing to 50-70% over time as market penetration grows.
2. What factors influence the speed of biosimilar adoption for this drug?
Physician familiarity, payer formulary policies, regulatory approval (including interchangeability status), and manufacturing capacity significantly impact adoption rates.
3. Are there regional differences in biosimilar prices for NDC 30698-0201?
Yes. U.S. pricing tends to be higher due to market complexity, rebates, and reimbursement policies compared to Europe and other regions, where pricing is often more aggressive.
4. How might upcoming regulatory changes impact the pricing trajectory?
Streamlined approval pathways and increased interchangeability designations could accelerate biosimilar uptake, leading to further price reductions.
5. What strategies can manufacturers adopt to remain competitive price-wise?
Focusing on manufacturing efficiencies, early regulatory engagement, securing interchangeability status, and forming strategic partnerships can help sustain margins in a competitive environment.
References
[1] IQVIA, "The Global Biologic Medicines Market," 2022.
[2] Deloitte, "The Biosimilar Landscape: Opportunities and Challenges," 2022.
[3] FDA, "Biosimilar Product Approvals," 2022.
[4] Center for Biosimilars, "Price Trends in Biosimilar Markets," 2022.
More… ↓
